Fehmi Keçe

Chapter 2 44 Table 2. Continued. Author, year (study type) Number of patients, ablation device and protocol* PAF (%) Preventive techniques AAD free survival (1 year) (%) Procedural, ablation time and fluoroscopy time (min) Complications (%) Mugnai, 2014 (88) (retrospective) N=136; CB 2x5 100 Phrenic nerve pacing (12mA, 1000ms) 57 112 (P<0.001) N.A. - Pericardial effusion/ Cardiac tamponade 7.3/ 0.7 - Transient ST-elevation 1.5 - Phrenic nerve palsy 8.1 (p<0.001); 0.7 at 12 months - Vascular access 1.5 Neumann,2008 (89) (observational) N=346; CB2x5 85 N.A. 74 170 (IQR 140- 195) 46 (IQR 26-60) 40 (IQR 30-57) - Cardiac tamponade 0.6 - Transient PNP 7.5 - Vascular access 2.3 Providencia, 2017(162) (multicentre retrospective) N=393; CB 2x4 100 N.A. 68–80 at 18m 120 (p<0.001) N.A. 23 - Pericardial effusion 0.3 (p=0.036) - Stroke/TIA 0.3/0.5 and coronary gas emboli 0.3 - PNP 1.8 (p=0.004) - Vascular access 2.0 - Other: 1.0 (haemoptysis and hemothorax) Schmidt, 2014 (90) (multicentre retrospective) N=905 CB; (discretion of the physician) 100 Phrenic nerve pacing N.A. 160 (IQR 130- 200) 45 (IQR 40-57) (p<0.001) 34 (26-46) (p<0.001) - Cardiac tamponade 0.8 - Stroke/TIA 0.3 and myocardial infarction 0.1 - Permanent PNP 2.1 (p<0.001) - Vascular access 1.4 - Other: third-degree AV-block 0.1 Squara, 2015 (91) (multicenter retrospective) N=198 CBA; 2x4 100 N.A. 82 DC testing 110 (p=0.003) N.A. 18 - Transient PNP 5.6 (p=0.001) - Vascular access 1.7